Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (7752)	1/17/2003 2:27:32 PM
From: A.J. Mullen	Read Replies (1) \| Respond to of 52153

Tuck, thanks for the relaying that. Your friend reiterates the New Scientist report -with more detail. I am still puzzled. The FDA is allowing work with true viruses (adenoviruses) to go ahead as well as that with naked DNA. Maybe the retrovirus, being simpler, can cut into the DNA in many more places than a true virus, so lowering the probability of a problem. With Naked DNA, I understand that the probability of insertion would be lower, but that lowers the probability of a therapeutic insertion too. It's the ratio of benign to malign insertions that matters. Ashley PS. Sorry for the delay. I posted before, but neglected to "publish." I must have missed the discussion of Igen here until August 01. I didn't realise you lived in SD too. I'll send you a pivate message.